Research & Development
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
14 November 2025 - Ionis Pharmaceuticals Inc (Nasdaq:IONS), a US-based provider of RNA-targeted medicines, and Japanese healthcare company Otsuka Pharmaceutical Co Ltd announced on Friday that the Com...
Merck to acquire Cidara Therapeutics in USD9.2bn deal to expand antiviral portfolio
14 November 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Friday announced a definitive agreement to acquire Cidara Therapeutics Inc (Nasda...
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
14 November 2025 - US-based based generic pharmaceutical company Ingenus Pharmaceuticals announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for its Conj...
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
13 November 2025 - Chinese biotechnology company Ascletis Pharma Inc (HKEX:1672) announced on Wednesday the co-formulation of ASC36, a once-monthly next-generation amylin receptor agonist, and ASC35, ...
EirGenix signs second global exclusive licensing deal with Sandoz
13 November 2025 - Taiwan-based contract development and manufacturing organisation EirGenix Inc (TWSE:6589) announced on Wednesday that it has signed a second global exclusive licensing agreement wit...
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
12 November 2025 - Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Wednesday that the United States Patent and Trademark Office will issue U.S. Patent No. 12,472,205 on 18 Nove...